Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

"Humanity relies on innovation to improve our lives and the planet," said Russ Fordyce, CEO of the Business Intelligence Group. "We're thrilled to spotlight OncoHost as a shining example of innovation ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Garching / Munich / Berlin, Germany, January 13, 2025 – (ITM), a leading radiopharmaceutical biotech company, and Ariceum ...